LDS/Medical Tests/Anti Mullerian Hormone (AMH)

Anti Mullerian Hormone (AMH)

Anti-Mullerian Hormone (AMH), also known as Müllerian inhibiting substance (MIS), is a glycoprotein hormone produced by the Sertoli cells of the male testis, and ovary granulosa cells of females. This hormone induces the regression of the Müllerian ducts, which is the foundation of the female reproductive tract. Secretion of Müllerian inhibiting substance begins by the eighth week of gestation and serum levels are readily detectable in boys until puberty and then decline precipitously. In females, levels are low until puberty and thereafter decline even more until menopause, after which levels may become undetectable. Absence of this hormone allows growth of the Müllerian ducts into the Fallopian tubes, uterus, cervix, upper third of the vagina, and the ovarian lining in females. The presence of AMH prevents Mullerian growth in males with subsequent growth of male reproductive structures. Normal females only produce AMH after birth from prepuberty through menopause at levels similar to adult males; it is produced in granulosa cells of small follicles in the ovary. AMH plays an inhibitory role during initial recruitment, when resting primordial follicles are initiated to grow, and second, it may modify preantral and small antral follicle growth by decreasing the FSH-responsiveness of the follicle. The effect may be important during cyclic recruitment, when certain large preantral and small antral follicles are recruited to grow to the preovulatory follicle stage. Therefore, AMH can be used as a marker for ovarian aging and as a marker for ovarian response in women undergoing in vitro fertilization treatment. AMH has also proved to be a marker for granulosa cell tumors and has potential to be used as a therapeutic agent for ovarian epithelial tumors. AMH assessment is useful in fertility assessment because it provides a guide to ovarian reserve and identifies women who may need to consider either egg freezing or trying for a pregnancy sooner rather than later if their long-term future fertility is poor. It also has the potential to rationalize the program of ovulation induction and decisions about the number of embryos to transfer in assisted reproduction techniques to maximize pregnancy success rates while minimizing the risk of ovarian hyperstimulation syndrome (OHSS). Menopausal women or women with ovarian failure or any event that adversely impacts ovarian function have low levels of AMH (<0.3ng/mL). Perimenopausal and menopausal women with low ovarian reserve also have low AMH in concentration of <0.1 ng/mL. However, the range of AMH in these women might be as high as 3ng/mL. In patients with polycystic ovary syndrome, AMH levels are 2-3 times elevated and can range as high as 30ng/mL. Increase in AMH levels are a good indicator of some types of ovarian cancer such as granulosa cell tumors.
  • Estimate ovarian reserve and the premenopausal transition in women
  • Assessing for premature ovarian failure
  • Evaluation of male gonadal function in all ages
  • Monitoring IVF treatment
  • Detection and onset of puberty in the young
  • Differential diagnosis of intersex disorders including ambiguous genetalia
  • As an aid in diagnosis of cryptorchidism and anorchidism
  • Diagnosis and management of patients with suspected AMH-secreting granulosa cell tumors of the ovary
  • Evaluation of ovary function in polycystic ovary patients
  • Evaluation of infertility and evaluation of menopause status

Increased in:

  • Polycystic ovary syndrome
  • In vitro fertilization
  • Pregnancy
  • Granulosa cell tumors

Decreased in:

  • Aging

Menopausal women or women with ovarian failure or any cause that impacts the ovarian function have low levels of AMH ( Perimenopausal and menopausal women with low ovarian reserve have low AMH as low as In boys with cryptorchidism, AMH levels are very low and sometimes undetectable, especially in anorchia or in patients with functional failure of testes or abnormally sited gonads. AMH levels decrease with age and don not change or very little change during the menstrual cycle.

Female:                   ng/mL                        pmol/L
0-16 years:              0.0-7.1                       0,00-1.00
17-29 years:            0.85-14.24                 0.11-2.01
30-39 years:            0.51-7.27                   0.071-1.02
40-49 years:            0.00-6.21                   0.00 – 0.87
>50 years:               0.00-0.82                   0.00 – 0.11

 

Male:                       ng/mL                        pmol/L
0-13 days:                15.50-48.10               2.20 – 6.77
14 days-11 months: 39.10-91.10               5.50 – 12.83
12 months-6 years:  48.00-83.20               6.76 – 11.71
7-8 years:                 33.80-60.20               4.76 – 8.47
9-12 years:               6.1-60.7                     0.86 – 8.55
13-16 years:             2.3-33.1                     0.32 – 4.66
Adult males:            1.50-18.35                  0.21 – 2.58

 

Ovarian Fertility Potential    ng/mL         pmol/L

Optimal Fertility:                   4.5 - 6.5       31.9 – 46.1

Satisfactory Fertility:             2.0 - 4.0       14.2 - 28.4

Low Fertility:                         0.3 - 2.0       2.2 – 14.2

Very Low / undetectable:      0.0 - 0.4       0.0 - 2.8

Enzyme-Linked Immunosorbent Assay

Serum (SST)

Stability

  • Ambient: 5 days
  • Refrigerated: 5 days
  • Frozen: 30 days
Testosterone total and free, Luteinizing Hormone, Follicle Stimulating Hormone, Y Chromosome Microdeletion, Cystic Fibrosis Mutation Analysis, Progesterone, Estradiol, Prolactin, Inhibin A and B, STD panel.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login